KCT0004649已完成未知
Efficacy of oral erdosteine ??in patients with acute rhinosinusitis
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
Please refer to the research result upload file.
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 18(Year) 至 0No Limit（—）
- 性别
- All
入选标准
- •Inclusion criteria
- •Diagnosis standard for acute sinusitis
- •? One or more of the symptoms of nasal obstruction/nasal discharge/posterior nasal drip
- •? One or more symptoms of sinus pain/Pressure or hyposmia/anosmia
- •? Observation of purulent discharge and mucous membrane edema
- •? Symptom duration less than 12 weeks
排除标准
- •Exclusion criteria
- •(1) Condra-indication for Erdosteine treatment
- •? Patient with severe liver failure/ liver cirrhosis, patient with enzyme deficiency related to metionine metabolism
- •? Patients with severe renal failure
- •? Patient with peptic ulcer
- •? Pregnancy/lactating women
- •(2) A history of nose surgery within the last three months
- •(3) Chronic sinusitis and nasal polyp identified by nasal endoscopy, X-ray, CT, etc.
- •(4) Subjects who participated in other clinical trials within one month prior to participating in this clinical trial
- •(5) Subjects deemed inappropriate for participation in this study by the investigator
研究者
相似试验
Unknown
3 期
The Efficacy and Safety of Erdosteine in Chronic Obstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary Disease (COPD)NCT01032304Edmond Pharma492
进行中（未招募）
1 期
The efficacy and safety of erdosteine in the long-term therapy of chronic obstructive pulmonary disease (COPD). A 12-month, randomised, double-blind, placebo-controlled, parallel group, multicenter study. - Study RESTOREChronic Obstructive Pulmonary DiseaseMedDRA version: 9.1 Level: LLT Classification code 10010952 Term: COPDEUCTR2008-008192-34-GBEdmond Pharma467
进行中（未招募）
不适用
Evaluation of erdosteine effect on systemic inflamation biomarkers during COPD exacerbations - ERD/inflammation/COPDCOPD exacerbationMedDRA version: 9.1Level: SOCClassification code 10038738EUCTR2008-008529-32-IT.O.PNEUMOLOGIA- AZ. USL1 DI MASSA E CARRARA
进行中（未招募）
1 期
The efficacy and safety of erdosteine in the long term therapy of Chronic Obstructive Pulmonary Disease (COPD). A 12-month, randomised, double blind, placebo-controlled, parallel group, multicenter, study - Study RESTOREChronic Obstructive Pulmonary Disease (COPD)MedDRA version: 12.1Level: LLTClassification code 10010952Term: COPDEUCTR2008-008192-34-SKEDMOND PHARMA S.r.l.542
进行中（未招募）
不适用
The efficacy and safety of erdosteine in the long term therapy of Chronic Obstructive Pulmonary Disease (COPD). A 12-month, randomised, double blind, placebo-controlled, parallel group, multicenter, study - Study RESTOREChronic Obstructive Pulmonary Disease (COPD)MedDRA version: 9.1Level: LLTClassification code 10010952Term: COPDEUCTR2008-008192-34-DKEDMOND PHARMA S.r.l.542